Biomarker Insights
Grunnleggende informasjon
Internasjonal tittel: |
Biomarker Insights |
e-ISSN: |
1177-2719 Periode: [2006 .. ] |
Språk: |
Engelsk |
Utgiverland: |
Storbritannia |
URL: |
https://journals.sagepub.com/home/bmi |
Forlag: |
Sage Publications |
ITAR-kode: |
1015023 |
NPI Fagfelt: |
Farmasi, farmakologi og toksikologi |
Kriterier
✅ Vitenskapelig redaksjon |
✅ Fagfellevurdert |
✅ Internasjonal forfatterkrets |
✅ Godkjent ISSN |
Åpen tilgang
I perioden 29.04.2022 - 04.05.2022 har enkelte tidsskrift hatt feil for DOAJ og Sherpa Romeo.
Nivåplasseringer og UH-sektorens publiseringspoeng
År | Nivå | Forfatterandeler | Publiseringspoeng |
---|---|---|---|
2022 | 0 |
|
|
2021 | 0 |
|
|
2020 | 0 | 0.0 | 0.0 |
2019 | 0 | 0.0 | 0.0 |
2018 | 0 | 0.0 | 0.0 |
2017 | 0 | 0.0 | 0.0 |
2016 | 0 | 0.0 | 0.0 |
2015 | 0 | 0.0 | 0.0 |
2014 | 0 | 0.0 | 0.0 |
2013 | 0 | 0.0 | 0.0 |
2012 | 1 | 0.0 | 0.0 |
2011 | 1 | 0.0 | 0.0 |
2010 | 1 | 0.0 | 0.0 |
2009 | 1 | 0.0 | 0.0 |
2008 | 1 | 0.0 | 0.0 |
Kommentarer
Kommentarer som gjelder oppdatering av informasjon, er kun synlig for deg og saksbehandler. Kommentarer som gjelder faglige innspill og nivå, blir offentlige.
Logg inn for å kommentereBiomarker Insights is a peer-reviewed open access academic journal focusing on biomarkers and their clinical applications. The journal aims to be a venue for rapid communications in the field. The journal was established in 2006 and was originally published by Libertas Academica. Wikipedia
OCLC number: 71909732
ISSN: 1177-2719
The International Editorial board can be accessed at : https://journals.sagepub.com/editorial-board/BMI
The journal peer review policy can be accessed at: https://journals.sagepub.com/author-instructions/BMI#PeerReviewPolicy
The journal’s policy is to have manuscripts reviewed by two expert reviewers. Biomarker Insights utilizes a single-blind peer review process in which the reviewer’s name and information is withheld from the author.
We request that the journal level in kanalregisteret/the Norwegian register is revised based on the information we have provided.
Thanking you,
Harleen Grewal
Professor dr.med. Det medisinske fakultet
Klinisk institutt 2, Universitetet i Bergen
Overlege, Mikrobiologisk avdeling
Haukeland universitetssykehus, Bergen
Epost: Harleen.Grewal@uib.no
Mob: +47 99450554
Thank you for the information.
In 2012 we downgraded the journal because we perceived it as dubious. It had another publisher at that time.
To have it reconsider for level 1, you can register it as a new submission. We will then receive it at our list over new proposals that we will treat for inclusion 10.June.
Kind regards,
Lena-Cecilie Linge